Suppr超能文献

大麻及其可允许状况。

Cannabis and Its Permissibility Status.

机构信息

Department of Applied Chemistry, College of Applied Sciences, Palestine Polytechnic University, Hebron, Palestine.

Department of Chemistry, University of Zurich, Zurich, Switzerland.

出版信息

Cannabis Cannabinoid Res. 2021 Dec;6(6):451-456. doi: 10.1089/can.2020.0017. Epub 2020 May 12.

Abstract

Cannabis has been used and misused to treat many disorders. Δ-Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most important components of cannabis and could be used for recreational and medical purposes. The permissibility (Halal) status of cannabis is controversial, and its rational use is ambiguous. Global awareness and interest in cannabis use are increasing and its permissibility status, especially for recreational and medical purposes, needs to be addressed. Rationalizing the scientific value and Halal status of cannabis is useful for the rational use and maintenance of the compatible system. It is rare in Muslim countries to discuss the permissibility status of cannabis from the perspective of its value and composition. Using the analogy concept, the CBD component extracted from a cannabis plant in a clean and pure form is permissible to use in industry, particularly in cosmetics and pharmaceuticals. If THC component is present in <1% and CBD is >99%, the mixture is considered permissible as long as THC is not intentionally added or intentionally left, but is mainly present due to the limited capabilities and efficiency of the purification methods. However, any amount of THC prepared with the intention to be used as an intoxicant is considered non-Halal.

摘要

大麻已被用于治疗多种疾病,但也被误用。Δ-四氢大麻酚(THC)和大麻二酚(CBD)是大麻中最重要的成分,可用于娱乐和医疗目的。大麻的可接受性(清真)地位存在争议,其合理使用也存在歧义。全球对大麻使用的认识和兴趣正在增加,需要解决其可接受性地位,特别是娱乐和医疗目的。使大麻的科学价值和清真地位合理化,有助于合理使用和维护兼容系统。在穆斯林国家,很少从其价值和成分的角度讨论大麻的可接受性地位。使用类比概念,从大麻植物中以清洁和纯净形式提取的 CBD 成分可用于工业,特别是在化妆品和制药领域。如果 THC 成分含量<1%,而 CBD 含量>99%,则只要 THC 不是故意添加或故意留下,而是由于净化方法的能力和效率有限而主要存在,混合物就被认为是可接受的。但是,任何意图用作麻醉剂的 THC 制备都被认为是不可清真的。

相似文献

1
Cannabis and Its Permissibility Status.
Cannabis Cannabinoid Res. 2021 Dec;6(6):451-456. doi: 10.1089/can.2020.0017. Epub 2020 May 12.
2
Effects of Δ⁹-tetrahydrocannabinol (THC), cannabidiol (CBD), and THC/CBD mixtures on fentanyl versus food choice in rhesus monkeys.
Drug Alcohol Depend. 2023 Mar 1;244:109787. doi: 10.1016/j.drugalcdep.2023.109787. Epub 2023 Feb 1.
3
Knowledge of Tetrahydrocannabinol and Cannabidiol Levels Among Cannabis Consumers in the United States and Canada.
Cannabis Cannabinoid Res. 2022 Jun;7(3):345-354. doi: 10.1089/can.2020.0092. Epub 2020 Oct 29.
5
THC and CBD: Villain versus Hero? Insights into Adolescent Exposure.
Int J Mol Sci. 2023 Mar 9;24(6):5251. doi: 10.3390/ijms24065251.
7
What Do You Know About Maryjane? A Systematic Review of the Current Data on the THC:CBD Ratio.
Subst Use Misuse. 2020;55(8):1223-1227. doi: 10.1080/10826084.2020.1731547. Epub 2020 Mar 3.
9
Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ-Tetrahydrocannabinol.
Neuropsychopharmacology. 2018 Jan;43(1):142-154. doi: 10.1038/npp.2017.209. Epub 2017 Sep 6.

引用本文的文献

1
Effects of Cannabidiol on Locomotor Activity.
Life (Basel). 2022 Apr 27;12(5):652. doi: 10.3390/life12050652.

本文引用的文献

1
Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program.
Epilepsy Behav. 2019 Sep;98(Pt A):201-206. doi: 10.1016/j.yebeh.2019.07.008. Epub 2019 Aug 2.
3
Synergy and antagonism in natural product extracts: when 1 + 1 does not equal 2.
Nat Prod Rep. 2019 Jun 19;36(6):869-888. doi: 10.1039/c9np00011a.
4
CBD: A New Hope?
ACS Med Chem Lett. 2019 Apr 29;10(5):694-695. doi: 10.1021/acsmedchemlett.9b00127. eCollection 2019 May 9.
5
Halalopathy: A science of trust in medicine.
J Integr Med. 2019 May;17(3):150-154. doi: 10.1016/j.joim.2019.03.005. Epub 2019 Mar 23.
6
Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment.
Life Sci. 2019 May 1;224:120-127. doi: 10.1016/j.lfs.2019.03.053. Epub 2019 Mar 22.
7
CBD as the New Medicine in the Pain Provider's Armamentarium.
Pain Ther. 2019 Jun;8(1):157-158. doi: 10.1007/s40122-019-0117-1. Epub 2019 Mar 12.
8
A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential.
J Clin Pharmacol. 2019 Jul;59(7):923-934. doi: 10.1002/jcph.1387. Epub 2019 Feb 7.
9
Response of Plant Secondary Metabolites to Environmental Factors.
Molecules. 2018 Mar 27;23(4):762. doi: 10.3390/molecules23040762.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验